Department of Otorhinolaryngology, Head and Neck Surgery, University of Göttingen, Robert-Koch-Str. 40, 37099 Göttingen, Germany.
Eur Arch Otorhinolaryngol. 2013 Sep;270(10):2719-27. doi: 10.1007/s00405-013-2382-7. Epub 2013 Feb 14.
The main objective of this study is to assess the feasibility of transoral laser microsurgery (TLM) in the treatment of T4a laryngeal cancer and to report the oncological and functional outcomes. This is a retrospective case-series study, held in a single-institute, academic tertiary referral center. Seventy-nine patients with previously untreated T4a glottic (n = 31, 39 %) or supraglottic laryngeal carcinoma (n = 48, 61 %) were included in this study. Five patients (6 %) were treated exclusively by TLM, 16 (20 %) had TLM and unilateral neck dissection, 27 (35 %) had TLM and bilateral neck dissection. Adjuvant (chemo)radiotherapy was additionally administered in 26 (33 %) cases following TLM and neck dissection, and in 5 (6 %) cases after TLM without neck dissection. The main outcome measures included organ preservation, local control, functional outcome, overall, recurrence-free, and disease-specific survival. The median follow-up period was 49 months, 5 year organ preservation rate and local control rate were 80.0 and 67.2 %, 5 year overall, recurrence-free and disease-specific survival were 55.8, 61.9 and 71.8 %. The 5 year overall survival rates were 62.5 % in pN0 cases and 57.2 % in cases with pN-positive neck disease. With respect to survival, these results are comparable to total laryngectomy, while being superior to primary (chemo)radiotherapy. TLM results in a low morbidity, rapid recovery and good function and can be a valid option for organ preserving surgery of pT4a glottic and supraglottic cancer.
本研究的主要目的是评估经口激光微创手术(TLM)治疗 T4a 喉癌的可行性,并报告肿瘤学和功能结果。这是一项回顾性病例系列研究,在一家单机构的学术三级转诊中心进行。本研究纳入了 79 例未经治疗的 T4a 声门(n = 31,39%)或喉上部癌(n = 48,61%)患者。5 例(6%)患者仅接受 TLM 治疗,16 例(20%)患者接受 TLM 和单侧颈部清扫术,27 例(35%)患者接受 TLM 和双侧颈部清扫术。26 例(33%)TLM 和颈部清扫术后以及 5 例(6%)TLM 无颈部清扫术后接受辅助(放)化疗。主要观察指标包括器官保留、局部控制、功能结果、总生存率、无复发生存率和疾病特异性生存率。中位随访时间为 49 个月,5 年器官保留率和局部控制率分别为 80.0%和 67.2%,5 年总生存率、无复发生存率和疾病特异性生存率分别为 55.8%、61.9%和 71.8%。pN0 病例的 5 年总生存率为 62.5%,pN 阳性颈部疾病病例为 57.2%。就生存率而言,这些结果与全喉切除术相当,优于原发性(放)化疗。TLM 具有低发病率、快速恢复和良好的功能,是保留器官治疗 T4a 声门和喉上部癌症的有效选择。